Replies to post #501522 on Anavex Life Sciences Corp (AVXL)

[mike_dotcom]

"makes blarcamesine a lock" Yea, you can tell by our sinking share price.

[rosemountbomber]

And LLY will have a hard time getting reimbursement for it.  It could die on the vine.  

[WilliamMunny]

Well, leighlogan, the approval of LEQEMBI (upon appeal) pretty much made the approval of Kisunla (upon appeal) a lock. With Blarcamesine objectively more efficacious in slowing the decline in cognition and far safer for the patient than either of those mAbs, as well as far easier and less expensive to deliver and monitor, it will now be extremely difficult for the EMA to reject its MAA. I say that before even considering the genomic result of much better cognitive preservation for carriers of (pre-specified) WT Sigmar-1 (i.e., ABCLEAR1 results), let alone the relatively stunning results for those (more than 70% of) WT Sigmar-1 patients who were also carriers of WT COL24A1 (i.e., ABCLEAR3 results).

[powerwalker]

leigh and William, is it possible that this approval is providing the ground work for EMA to approve Blarcamesine, in that the agency can say to Lilly, Biogen, and the World that it has approved all three AD contenders for use in the EU and may the BEST DRUG win?


GO BLARCAMESINE!!!